Ticlopidine · DIN 02237701 · 250 mg · tablet
Limited Use, Reason for Use code 219, 220, 221 requiredDormant since September 1, 2022 · checked November 17, 2026 · What does dormant mean?
StatusLimited Use, Reason for Use code 219, 220, 221 required
Write on scriptone applicable Reason for Use code, 219 or 220 or 221 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 219, 220, 221
Coverage limit:
Ticlopidine is restricted to patients with transient cerebral ischemia. Ticlopidine may be somewhat more effective than ASA in preventing fatal and non-fatal strokes. However, it is associated with neutropenia in 0.8-2.4% of patients, a serious side-effect which may be fatal. Patients on ticlopidine require blood tests every two weeks for the first three months of therapy. There have been more than 60 cases of ticlopidine associated thrombotic thrombocytopenic purpura (TTP) with 33% mortality rate. As well, there are other side-effects such as diarrhea that occurs in 12.5% of patients. Ticlopidine should be used only after careful consideration. The appropriate use of ticlopidine in the management of patients with cerebral ischemic events (TIA or stroke) is based on the following:
(a) Determining that the symptoms are due to focal cerebral ischemia, and differentiating the symptoms of dizziness due to vestibular dysfunction, lightheadedness, or syncope from antihypertensive drugs or cardiac dysfunction, and from symptoms due to migraine, epilepsy, hypoglycemia, or other causes, such as tumor.
(b) If investigation demonstrates that the events are caused by emboli from the heart, the patient should be treated with anticoagulants, such as warfarin.
(c) If the events are due to artery-to-artery emboli from the carotid bifurcation with a severe stenosis, the patient should probably be treated with ASA and offered carotid endarterectomy if medically suitable (70% to 99% stenosis).
(d) ASA should be the first line of defense for patients with TIA and threatened stroke, and after an initial stroke of any severity.
(e) The only drugs other than ASA that are available as platelet inhibitors and which have been shown to be of value for such patients are ticlopidine and clopidogrel.
(f) Before abandoning ASA in favour of ticlopidine, efforts should be made to improve the tolerability of ASA by reducing the dose, taking it with food, and using enteric coated ASA.
Ticlopidine will be reimbursed for patients:
Reason for Use code 219
Who are known to be, or become, intolerant of ASA;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 220
Where ASA is contraindicated;
Coverage limit:
LU Authorization Period: Indefinite
Reason for Use code 221
Who continue to have TIA or stroke symptoms while being treated with ASA.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Ticlopidine · DIN 02237701
Manufacturer: A A Pharma Inc.; listing date 1999-04-15
Health Canada: Dormant since 2022-09-01 · brand TICLOPIDINE · ATC B01AC05 TICLOPIDINE · form Tablet · route Oral · ingredients TICLOPIDINE HYDROCHLORIDE 250 MG · company Aa pharma inc · schedule Prescription
Ticlopidine: Formulary list price $1.07 per unit (the source does not state the unit; exact figure $1.0679). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02237701)
Source record
DIN 02237701: Ticlopidine
Raw flags: sec12=Y, sec3=Y
Item: 920000219; group id 972; item number 2305; lccId 00139; manufacturer id AAP
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.0679; ministry $1.0679
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02237701
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61047
Interchangeable products
Ticlid · DIN 02162776 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since September 1, 2022 — choose a marketed DIN from the same-category list.